⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCRX News
BioCryst Pharmaceuticals Inc
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
BCRX
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
globenewswire.com
BCRX
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
prnewswire.com
BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BCRX
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
globenewswire.com
BCRX
ASTR
Blacksmith Medicines Secures European Patent Allowance for LpxC-Targeting Antibacterial Compounds
prnewswire.com
BCRX
BSRS
CYT
LLY
RHHBY
ZTS
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
prnewswire.com
NTLA
ASTX
RZLT
IONS
KALV
BCRX
TAK
KAVL
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
businesswire.com
ATXS
BCRX
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
globenewswire.com
BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BCRX